Genmab AS Ownership
| GMAB Stock | USD 30.32 0.10 0.33% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 619.9 M | Current Value 620.7 M | Avarage Shares Outstanding 582.1 M | Quarterly Volatility 82.1 M |
Genmab Stock Ownership Analysis
The book value of the company was currently reported as 93.41. The company has Price/Earnings To Growth (PEG) ratio of 0.75. Genmab AS had not issued any dividends in recent years. The entity had 5:1 split on the 1st of May 2018. Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on NASDAQ Exchange in the United States. To learn more about Genmab AS call the company at 45 70 20 27 28 or check out https://www.genmab.com.Besides selling stocks to institutional investors, Genmab AS also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Genmab AS's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Genmab AS's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Genmab AS Quarterly Liabilities And Stockholders Equity |
|
Genmab Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Genmab AS is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Genmab AS backward and forwards among themselves. Genmab AS's institutional investor refers to the entity that pools money to purchase Genmab AS's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Brandywine Global Investment Mgmt Llc | 2025-06-30 | 1.7 M | Two Sigma Investments Llc | 2025-06-30 | 1.6 M | Voloridge Investment Management, Llc | 2025-06-30 | 949.2 K | Acadian Asset Management Llc | 2025-06-30 | 934.1 K | Jpmorgan Chase & Co | 2025-06-30 | 933.3 K | Goldman Sachs Group Inc | 2025-06-30 | 889.3 K | Northern Trust Corp | 2025-06-30 | 803.6 K | Envestnet Asset Management Inc | 2025-06-30 | 749.6 K | Fmr Inc | 2025-06-30 | 680.5 K | Alliancebernstein L.p. | 2025-06-30 | 10.7 M | Orbis Allan Gray Ltd | 2025-06-30 | 7.9 M |
Genmab AS Outstanding Bonds
Genmab AS issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Genmab AS uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Genmab bonds can be classified according to their maturity, which is the date when Genmab AS has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Genmab AS Corporate Filings
6K | 18th of November 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 14th of November 2025 Other Reports | ViewVerify | |
| 31st of October 2025 Other Reports | ViewVerify | |
| 21st of October 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.076 | Earnings Share 2.28 | Revenue Per Share | Quarterly Revenue Growth 0.174 | Return On Assets |
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.